2021 – iCo Therapeutics

iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update regarding Business Combination with Satellos Bioscience Inc.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo

ico_admin2021-07-09T07:09:25+00:00July 9th, 2021|2021, Press Releases|

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. iCo

ico_admin2021-05-11T23:04:37+00:00May 10th, 2021|2021, Press Releases|

ico_admin2021-05-03T19:54:13+00:00May 1st, 2021|2021, Press Releases|

Press Release For Immediate Release NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION

ico_admin2021-04-28T01:28:34+00:00April 28th, 2021|2021, Press Releases|

ico_admin2021-04-23T07:16:59+00:00April 23rd, 2021|2021, Press Releases|

ico_admin2021-03-22T17:00:01+00:00March 22nd, 2021|2021, Press Releases|

March 15, 2021, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or

ico_admin2021-03-16T00:37:52+00:00March 15th, 2021|2021, Press Releases|

March 11, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or

ico_admin2021-03-12T01:01:51+00:00March 11th, 2021|2021, Press Releases|

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-18T21:53:35+00:00January 11th, 2021|2021, Press Releases|

ico_admin2021-02-21T21:40:18+00:00January 1st, 2021|2021, Presentations|